Lantheus Holdings (LNTH) Stock Price, News & Analysis

Lantheus Holdings, Inc. (NASDAQ: LNTH) is a radiopharmaceutical-focused company that serves the healthcare sector by developing and commercializing diagnostic products used to help clinicians "Find, Fight and Follow" disease. While classified under surgical and medical instrument manufacturing for industry purposes, Lantheus consistently describes itself as a radiopharmaceutical-focused business that supports disease detection, characterization and management across oncology, cardiology and neurological conditions.

The company states that it has been providing radiopharmaceutical solutions for nearly 70 years. Lantheus is headquartered in Massachusetts and reports having offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom. Its common stock trades on the Nasdaq Global Market under the symbol LNTH, as disclosed in its SEC filings.

Business focus and product categories

According to available information, Lantheus develops diagnostic products organized into several categories. A prior description notes three main areas: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products are described as assisting healthcare professionals in finding and following diseases, with a focus in cardiology. Radiopharmaceutical oncology diagnostics and therapeutics are described as helping healthcare professionals find, fight and follow cancer. Strategic partnerships are described as focusing on enabling precision medicine through biomarkers, digital solutions and pharma services platforms, and include licensing arrangements.

In more recent communications, Lantheus emphasizes a growing commercial portfolio of positron emission tomography (PET) radiodiagnostics and microbubbles, as well as an expanding pipeline of radiopharmaceuticals. The company highlights commercial products such as PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent for prostate cancer, and DEFINITY, as key contributors to its established portfolio. Lantheus also reports that it has acquired Neuraceq (florbetaben F 18 injection), a beta-amyloid targeted PET radiodiagnostic for Alzheimer’s disease, through the acquisition of Life Molecular Imaging.

Radiopharmaceutical oncology and PET imaging

Lantheus describes itself as focused on radiopharmaceuticals that support oncology care. PYLARIFY (piflufolastat F 18) is described as a fluorinated small molecule PSMA-targeted PET imaging agent used to visualize PSMA-positive lesions in men with prostate cancer. It is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer who are candidates for initial definitive therapy or who have suspected recurrence based on elevated prostate-specific antigen levels. Lantheus notes that PYLARIFY combines PET imaging, PSMA targeting and an F 18 radioisotope to support diagnostic performance.

The company also reports advancing multiple PET imaging agents in its pipeline. LNTH-2501 (Ga 68 edotreotide) is described as a diagnostic kit for preparation of Ga 68 edotreotide injection, for use with PET imaging to localize somatostatin receptor-positive neuroendocrine tumors (NETs) in adult and pediatric patients. Lantheus states that LNTH-2501 is under FDA review and is intended to expand its oncology diagnostic portfolio. In addition, the company has submitted a New Drug Application for MK-6240, an F18-labeled tau-targeted PET imaging agent for detecting tau neurofibrillary tangle pathology in patients with cognitive impairment being evaluated for Alzheimer’s disease. MK-6240 is described as having Fast Track designation and being supported by Phase 3 data.

Alzheimer’s disease diagnostics and Neuraceq

Through the acquisition of Life Molecular Imaging, Lantheus reports that it has added Neuraceq (florbetaben F 18 injection) to its commercial portfolio. Neuraceq is indicated for PET of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment, for evaluation of Alzheimer’s disease and other causes of cognitive decline and for selection of patients who are candidates for amyloid beta-directed therapy, as described in relevant prescribing information. Lantheus notes that Neuraceq’s label has been expanded to include use in both diagnostic assessment and identification of appropriate candidates for FDA-approved amyloid-targeting therapies, as well as broader use for monitoring therapy and following progression to Alzheimer’s disease.

The company positions Neuraceq and MK-6240 together as part of its strategy in the Alzheimer’s disease radiodiagnostic market, describing this area as a growing focus following the Life Molecular Imaging acquisition.

Strategic transactions and portfolio evolution

Lantheus has disclosed several significant corporate transactions that shape its business profile. It reports completing the acquisition of Evergreen Theragnostics, a clinical-stage radiopharmaceutical company based in New Jersey. Through this transaction, Lantheus states that it acquired OCTEVY, a registrational-stage PET imaging agent targeting neuroendocrine tumors, as well as a portfolio of clinical and pre-clinical theranostic pairs and radioligand therapy manufacturing infrastructure, including a contract development and manufacturing (CDMO) business.

The company also reports completing the acquisition of Life Molecular Imaging, a global radiopharmaceutical company dedicated to developing and offering radiopharmaceuticals for early detection and characterization of chronic and life-threatening diseases. Through this acquisition, Lantheus states that it gained Neuraceq and an international commercial footprint and infrastructure.

On the divestiture side, Lantheus has announced and subsequently closed the sale of its single photon emission computed tomography (SPECT) business to SHINE Technologies, LLC, a subsidiary of Illuminated Holdings, Inc. The transaction includes Lantheus’ SPECT diagnostic agents TechneLite, NEUROLITE, Xenon Xe-133 Gas and Cardiolite, along with the portion of its North Billerica, Massachusetts campus that manufactures SPECT products and related Canadian operations. Lantheus describes this divestiture as allowing the company to focus on its commercial portfolio of PET radiodiagnostics and microbubbles and to advance its radiopharmaceutical pipeline.

Geographic footprint and market presence

In its public communications, Lantheus states that it is headquartered in Massachusetts and maintains offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom. Through its acquisitions and licensing agreements, the company indicates that it is active in multiple geographic markets. For example, Lantheus has entered into an exclusive licensing agreement with GE HealthCare for GE HealthCare to develop, manufacture and commercialize piflufolastat F 18 (PYLARIFY) in Japan for prostate cancer diagnostics and companion diagnostic use. Under this agreement, Lantheus reports that GE HealthCare will pay an upfront license fee, development milestones and tiered royalties based on product sales in Japan.

Strategic partnerships and licensing

Lantheus’ earlier description highlights Strategic Partnerships and other revenue as a key category, focused on enabling precision medicine through biomarkers, digital solutions and pharma services platforms, and including licensing of certain products. A specific example mentioned is the license of RELISTOR to Bausch Health Companies, Inc. In more recent disclosures, the company emphasizes licensing arrangements such as the exclusive agreement with GE HealthCare for PYLARIFY in Japan and clinical development partnerships that use MK-6240 or NAV-4694 as research tools.

Leadership and governance developments

SEC filings and press releases describe leadership transitions at Lantheus. The company has announced that its Chief Executive Officer, Brian Markison, notified the board of his intention to retire effective December 31, 2025, and that he will also resign from the board on that date. Lantheus reports that he will serve as a strategic advisor through at least March 31, 2026 under a consulting agreement. The board has appointed Mary Anne Heino, previously CEO and then Chairperson of the Board, as Executive Chairperson and principal executive officer, with plans for her to serve as interim CEO beginning January 1, 2026 while the board conducts a CEO search.

Lantheus has also disclosed changes in other senior roles, including the departure of its President and a temporary leave and subsequent return of its Chief Commercial Officer. These governance updates are documented in the company’s Form 8-K filings.

Financial reporting and capital allocation

Lantheus regularly reports its financial results via press releases and Form 8-K filings. The company provides information on worldwide revenue, net income, earnings per share, operating income and cash flows, and also discusses non-GAAP measures such as adjusted net income, adjusted operating income and free cash flow. Management states that these non-GAAP measures are used internally to evaluate performance and may assist investors in assessing operations over time.

The company has also disclosed capital allocation actions, including a stock repurchase program. In one Form 8-K, Lantheus reports that its board authorized a program to repurchase up to a specified dollar amount of common stock through a defined period, replacing a prior repurchase program. Repurchases may be conducted through open market transactions, privately negotiated transactions or other methods, subject to market conditions and applicable regulations.

Regulatory and pipeline milestones

Lantheus’ news releases highlight multiple regulatory milestones for its pipeline. The company reports that the U.S. Food and Drug Administration has accepted a New Drug Application for a new formulation of its piflufolastat F 18 PSMA PET imaging agent and has set a Prescription Drug User Fee Act (PDUFA) target action date. Lantheus describes this new formulation as increasing batch size and potentially enabling increased patient access, supply resilience and enhanced production efficiency.

The company also reports that the FDA has established a PDUFA date for LNTH-2501 (Ga 68 edotreotide) and has accepted an NDA for MK-6240, with both assets positioned as part of its radiopharmaceutical pipeline in oncology and Alzheimer’s disease diagnostics, respectively. These updates are presented with standard forward-looking statement cautions in the company’s communications.

Risk considerations and disclosures

Lantheus includes safe harbor and forward-looking statement sections in its press releases and SEC filings, outlining risks and uncertainties that could cause actual results to differ from expectations. These disclosures reference factors such as competitive dynamics for products like PYLARIFY and DEFINITY, manufacturing and supply considerations, availability of equipment such as PET scanners, regulatory approvals for pipeline assets, integration of acquisitions, execution of divestitures, and reimbursement and payment dynamics.

Investors reviewing LNTH stock and Lantheus’ business model often examine these risk disclosures, along with the company’s 10-K, 10-Q and 8-K filings, to understand the regulatory, operational and financial context for the radiopharmaceutical-focused strategy described in the company’s public statements.